FDA approves 23andMe's direct-to-consumer test for cancer risk

23andMe Inc. (Mountain View, Calif.) said FDA authorized its direct-to-consumer BRCA1/BRCA2 (Selected Variants) Genetic Health Risk (GHR) Report to

Read the full 197 word article

User Sign In